1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-5-oxopyrrolidine-3-carboxamide

Catalog No. :
ACJSKB944
CAS No. :
852842-42-3
Molecular Formula :
C16H16N4O4S
Molecular Weight :
360.39

IUPAC Name:1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-5-oxopyrrolidine-3-carboxamide

1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-5-oxopyrrolidine-3-carboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-5-oxopyrrolidine-3-carboxamide
IUPAC Name1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-5-oxopyrrolidine-3-carboxamide
Molecular FormulaC16H16N4O4S
Molecular Weight360.39
SMILESO=C(C(C1)CN(C2=CC=C3OCCOC3=C2)C1=O)NC4=NN=C(C)S4
InChI KeyWJLFFSKHIVYFTL-UHFFFAOYSA-N
Synonym1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-5-oxopyrrolidine-3-carboxamide;3-Pyrrolidinecarboxamide, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-5-oxo-
CAS No.852842-42-3

Synthetic Route by SureRoute

1. ACJSKB944 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACLEQR561 route compound structure diagram
    ACLEQR561108-33-8 In Stock
  2. Plus
  3. ACSURD016 route compound structure diagram
    ACSURD016260555-42-8 In Stock
  4. Then
  5. ACJSKB944 route product structure diagram
    ACJSKB944852842-42-3
Inquiry

2. ACJSKB944 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCWEU094 route compound structure diagram
    ACCWEU09452287-51-1 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJSKB944 route product structure diagram
    ACJSKB944852842-42-3
Inquiry

Comments (0)